Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    SB-525 | Hemophilia A

Six Month lead-in Study to Evaluate Prospective Efficacy and Safety Data of Current FIX Prophylaxis Replacement Therapy in Adult Hemophilia B Subjects (FIX:C≤2%) or Current FVIII Prophylaxis Replacement Therapy in Adult Hemophilia A Subjects (FVIII:C≤1%)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03587116
Recruitment Status : Recruiting
First Posted : July 16, 2018
Last Update Posted : August 31, 2021
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

To establish a minimum of 6 months of prospective efficacy data of current FIX prophylaxis replacement therapy in the usual care setting of hemophilia B subjects, who are negative for nAb to AAV-Spark100, prior to the Phase 3 gene therapy study.

To establish a minimum of 6 months of prospective efficacy data of current FVIII prophylaxis replacement therapy in the usual care setting of hemophilia A subjects, who are negative for nAb to SB-525 capsid (AAV6), prior to the Phase 3 gene therapy study.

The enrollment for hemophilia A participants is completed. At this time participants are only being enrolled for hemophilia B cohort.


Condition or disease Intervention/treatment Phase
Hemophilia B Hemophilia A Drug: Standard of Care FIX Replacement therapy Drug: Standard of Care FVIII Replacement therapy Phase 3

Detailed Description:
AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, MULTI-CENTER, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SELECTED SAFETY DATA OF CURRENT FACTOR IX (FIX) OR FACTOR VIII (FVIII) PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR-SPARK100 (BENEGENE-1) AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR NEUTRALIZING ANTIBODIES TO ADENO-ASSOCIATED VIRUS VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PHASE 3 GENE THERAPY STUDIES

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: The data obtained from this 6 month lead-in study will serve as the control group for the subsequent Phase 3 gene therapy study.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: AN OPEN-LABEL, NON-INVESTIGATIONAL PRODUCT, LEAD-IN STUDY TO EVALUATE AT LEAST 6 MONTHS OF PROSPECTIVE EFFICACY AND SAFETY DATA OF FACTOR IX OR FACTOR VIII PROPHYLAXIS REPLACEMENT THERAPY IN THE USUAL CARE SETTING OF MODERATELY SEVERE TO SEVERE ADULT HEMOPHILIA B SUBJECTS (FIX:C≤2%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR-SPARK100 AND MODERATELY SEVERE TO SEVERE HEMOPHILIA A ADULT SUBJECTS (FVIII:C≤1%) WHO ARE NEGATIVE FOR nAb TO AAV VECTOR SB-525 CAPSID (AAV6), PRIOR TO THE RESPECTIVE THERAPEUTIC PH 3 GENE THERAPY STUDIES (See Detailed Description Section for Official Protocol Title)
Actual Study Start Date : July 26, 2018
Estimated Primary Completion Date : October 15, 2022
Estimated Study Completion Date : October 15, 2022


Arm Intervention/treatment
Standard of Care FIX replacement therapy Drug: Standard of Care FIX Replacement therapy
There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.

Standard of Care FVIII replacement therapy Drug: Standard of Care FVIII Replacement therapy
There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.




Primary Outcome Measures :
  1. Annualized bleeding rate (ABR) [ Time Frame: 6 months ]

    The annualized bleeding rate (ABR) per subject will be calculated as the number of bleeds over number of days subject received FIX prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. ABR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).

    The annualized bleeding rate (ABR) per subject will be calculated as the number of bleeds over number of days subject received FVIII prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. ABR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).


  2. Incidence of serious adverse events [ Time Frame: 6 months ]
    The primary safety analysis will be performed on all subjects that sign the informed consent document and are subsequently identified as nAb negative and are enrolled (complete baseline visit) into the study.

  3. Events of special interest (ESI):inhibitor against FIX or FVIII, thrombotic events, and FIX or FVIII hypersensitivity reactions [ Time Frame: 6 months ]
    Frequency and percentage of these ESI events will be summarized by event. In addition any events leading to discontinuation from the study will be described.


Secondary Outcome Measures :
  1. Annualized infusion rate (AIR) [ Time Frame: 6 months ]

    The annualized infusion rate (AIR) per subject will be calculated as the number of infusions received over number of days subject received FIX prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. AIR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).

    The annualized infusion rate (AIR) per subject will be calculated as the number of infusions received over number of days subject received FVIII prophylaxis replacement therapy from baseline visit (Day 1) to end of study x 365.25 days. AIR will be summarized using descriptive statistics (n, mean, standard deviation, median, Q1, Q3, minimum, maximum).


  2. Dose and total factor consumption [ Time Frame: 6 months ]

    The total factor IX replacement therapy consumption and the corresponding dose will be descriptively summarized by the categories of the replacement therapy, where appropriate. Infusion diary (electronic infusion diary) of the factor IX replacement therapy will be listed.

    The total factor VIII replacement therapy consumption and the corresponding dose will be descriptively summarized by the categories of the replacement therapy, where appropriate. Infusion diary (electronic infusion diary) of the factor VIII replacement therapy will be listed.


  3. Number of bleeding events (spontaneous and/or traumatic) [ Time Frame: 6 months ]
    The number of bleeding episodes will be summed up by spontaneous, traumatic and overall as defined as any bleed occurring >72 hours after stopping treatment from the original bleed for which treatment was initiated or a bleed occurring at a different site from the original bleed regardless of the time from last injection.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Hemophilia B Population:

  1. Evidence of a personally signed and dated informed consent document indicating that the participant or his legally authorized representative has been informed of all pertinent aspects of the study.
  2. Willing and able to comply with scheduled visits, FIX prophylaxis treatment plan, laboratory tests and other study procedures.
  3. Males ≥ 18 and <65 years of age with moderately severe to severe hemophilia B and documented FIX activity (≤2%) prior to baseline visit.
  4. Previous experience with FIX therapy (≥50 documented exposure days to a FIX protein product such as recombinant, plasma-derived or extended half-life FIX product).
  5. Subjects on FIX prophylaxis replacement therapy (recombinant, plasma-derived or extended half-life FIX product) must have the intention to remain on FIX prophylaxis replacement therapy for the duration of the study.
  6. No known hypersensitivity to FIX replacement product.
  7. No history of FIX inhibitor (clinical or laboratory-based assessment) defined as a titer

    • 0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda inhibitor titer greater than the upper limit of normal for the laboratory performing the assay. Clinically, no signs or symptoms of decreased response to FIX administration. Subjects will not be required to undergo diagnostic evaluation of inhibitor status to participate in the study.

Hemophilia A Population:

  1. Evidence of a personally signed and dated informed consent document indicating that the participant or his legally authorized representative has been informed of all pertinent aspects of the study.
  2. Willing and able to comply with scheduled visits, FVIII prophylaxis treatment plan, laboratory tests and other study procedures.
  3. Males ≥18 and <65 years of age with moderately severe to severe hemophilia A and documented FVIII activity (≤1%) prior to baseline visit.
  4. Previous experience with FVIII therapy (≥150 documented exposure days to a FVIII protein product such as recombinant, plasma-derived or extended half-life FVIII product).
  5. Subjects on FVIII prophylaxis replacement therapy (recombinant, plasma-derived or extended half-life FVIII product) must have the intention to remain on FVIII prophylaxis replacement therapy for the duration of the study.
  6. No known hypersensitivity to FVIII replacement product.
  7. No history of FVIII inhibitor (clinical or laboratory-based assessment) defined as a titer ≥0.6 BU/mL, regardless of the laboratory normal range, or any measured Bethesda inhibitor titer greater than the upper limit of normal for the laboratory performing the assay. Clinically, no signs or symptoms of decreased response to FVIII administration. Subjects will not be required to undergo diagnostic evaluation of inhibitor status to participate in the study.

Exclusion Criteria:

  1. Anti-AAV-Spark100 neutralizing antibody titer above or equal to 1:1 performed by a central laboratory during screening in hemophilia B subjects or Anti- SB-525 capsid (AAV6) neutralizing antibody titer (above or equal to the lowest detectable titer) performed by a central laboratory during screening in hemophilia A subjects.
  2. Lack of patient compliance with documentation of bleeds and/or prophylaxis replacement therapy administration.
  3. If there is no documentation regarding hepatitis status, as defined below, within the last 12 months prior to screening for hepatitis B and 6 months prior to screening for hepatitis C, then subjects will be required to have the following hepatitis testing performed at screening:

    1. Hepatitis B screening (acute and chronic):

      HBsAg (also referred to as Hepatitis B surface antigen), HBV-DNA viral assay (also referred to as a nucleic acid test for Hepatitis B virus DNA), and Anti-HBc (also referred to as Total Hepatitis B core antibody).

      • A subject is not eligible if either HbsAg is positive or HBV-DNA is positive/detectable.
      • Anti-HBc must be obtained in all subjects for determination of whether the subject had prior hepatitis B. If the anti-HBc is positive and both HBsAg and HBV DNA are negative this would be consistent with a prior infection and the subject would be eligible for the study. Anti-HBc must be obtained in all subjects to discriminate between those with no prior hepatitis B and those with prior infection in the event of reactivation. FDA has noted reactivation of hepatitis B virus exists.
      • One documented negative HBV-DNA viral load is sufficient to assess eligibility. A subject who is currently undergoing anti-viral therapy for hepatitis B is not eligible.
    2. Hepatitis C (acute or chronic):

      • A subject who is currently undergoing anti-viral therapy for chronic hepatitis C is not eligible.
      • Subjects treated with anti-viral therapy for chronic hepatitis C, must have completed anti-viral therapy at least 6 months prior to screening and have a negative HCV-RNA at least 6 months prior to screening.
      • All subjects (who are not currently undergoing anti-viral therapy for chronic hepatitis C) must have a single HCV-RNA load assay (also referred to as a nucleic acid test [NAT] for HCV RNA) obtained during the 6 months preceding screening. This includes subjects with prior known chronic hepatitis C who have completed treatment with anti-viral therapy.
      • A subject is not eligible if his HCV-RNA load assay result is positive/detectable.
  4. Currently on antiviral therapy for hepatitis B or C.
  5. A subject is not eligible if any of the following pre-existing diagnoses, which are indicative of significant underlying liver disease, are present in the medical record:

    • Portal hypertension; or
    • Splenomegaly; or
    • Hepatic encephalopathy.

    All subjects who do not have the listed pre-existing diagnoses above must have the following assessments performed within the last 12 months prior to screening and if not will need to be tested for liver fibrosis status at screening:

    • Measurement of serum albumin. A subject is not eligible if the serum albumin level is below the testing laboratory's lower limit of normal; and
    • One of the following diagnostic tests for liver fibrosis. The following results are indicative of fibrosis and exclude the subject from participation:
    • FibroScan, with a score >8.3 kPa units;
    • FibroTest/FibroSURE with a result >0.48*; or
    • AST-to-Platelet Ratio Index (APRI) >1.

      • Please note, if a subject has a known history of Gilbert's syndrome, a FibroTest cannot be used for fibrosis testing.
  6. Documented serological evidence of human immunodeficiency virus HIV-1 or HIV-2 with Cluster of Differentiation 4 positive (CD4+) cell count ≤200 mm3 within the last 12 months prior to screening. Subjects who are HIV positive and stable, have an adequate CD4 count (>200/mm3) and undetectable viral load (<50 gc/mL) documented within the preceding 12 months, and are on an antiretroviral drug regimen are eligible to enroll. Subjects who have not been tested within the prior 12 months of screening will need to be tested for HIV status at screening.
  7. History of chronic infection or other chronic disease that the investigator deems an unacceptable risk. Any patient with a history of thrombotic events including but not limited to stroke or myocardial infarction.
  8. Any concurrent clinically significant major disease or condition that the investigator deems unsuitable for participation or other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  9. Participation in other studies if involving administration of investigational product(s) within the last 3 months prior to study entry and/or during study participation or in a previous gene therapy clinical study within the last 12 months prior to screening.

    • Participants already enrolled in this lead-in study (C0371004) may be allowed to participate in the screening and baseline periods of either C0371002 or C3731003 protocols prior to their completion of the end of study visit in this lead-in study.

  10. Any subject who previously received fidanacogene elaparvovec (SPK-9001) (hemophilia B) or SB-525 (hemophilia A) or any AAV gene-based therapy.
  11. Any subject with a planned surgical procedure requiring FIX (hemophilia B) or FVIII (hemophilia A) surgical prophylactic factor treatment in the next 24 months.
  12. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03587116


Contacts
Layout table for location contacts
Contact: Pfizer CT.gov Call Center 1-800-718-1021 ClinicalTrials.gov_Inquiries@pfizer.com

Locations
Hide Hide 67 study locations
Layout table for location information
United States, California
Clinical and Translational Research Unit (CTRU) Recruiting
Palo Alto, California, United States, 94304
Lucile Packard Childrens Hospital Recruiting
Palo Alto, California, United States, 94304
University of California San Francisco - UCSF HTC Recruiting
San Francisco, California, United States, 94117
University of California, San Francisco - Clinical Research Center Recruiting
San Francisco, California, United States, 94143
University of California, San Francisco - Outpatient Hematology Clinic Recruiting
San Francisco, California, United States, 94143
Stanford Health Care Recruiting
Stanford, California, United States, 94305
United States, Colorado
Hemophilia and Thrombosis Center at the University of Colorado Anschutz Medical Campus Active, not recruiting
Aurora, Colorado, United States, 80045
United States, Georgia
Emory University Hospital Midtown Recruiting
Atlanta, Georgia, United States, 30308
Emory University Hospital Recruiting
Atlanta, Georgia, United States, 30322
Investigational Drug Service Recruiting
Atlanta, Georgia, United States, 30322
United States, Indiana
Indiana Hemophilia & Thrombosis Center, Inc. Recruiting
Indianapolis, Indiana, United States, 46260
United States, Mississippi
Mississippi Center for Advanced Medicine Active, not recruiting
Madison, Mississippi, United States, 39110
United States, Nevada
Alliance for Childhood Diseases Recruiting
Las Vegas, Nevada, United States, 89135
United States, Pennsylvania
Penn Blood Disorder Center Recruiting
Philadelphia, Pennsylvania, United States, 19104
Penn Comprehensive Hemophilia & Thrombosis Program, Hospital of the University of Pennsylvania Recruiting
Philadelphia, Pennsylvania, United States, 19104
United States, Washington
Bloodworks NW Active, not recruiting
Seattle, Washington, United States, 98104
Australia, New South Wales
Royal Prince Alfred Hospital Recruiting
Camperdown, New South Wales, Australia, 2050
Australia, South Australia
Royal Adelaide Hospital Recruiting
Adelaide, South Australia, Australia, 5000
Australia, Victoria
The Alfred Hospital Recruiting
Melbourne, Victoria, Australia, 3004
Australia, Western Australia
Fiona Stanley Hospital Recruiting
Murdoch, Western Australia, Australia, 6150
Belgium
Cliniques universitaires Saint-Luc/Unité d'Hématology et Hémostase Recruiting
Brussels, Belgium, 1200
Brazil
Centro de Hemoterapia e Hematologia do Para - Fundação HEMOPA Recruiting
Belem, Para, Brazil, 66033-000
Centro de Hematologia e Hemoterapia - Hemocentro de Campinas - UNICAMP Recruiting
Campinas, SAO Paulo, Brazil, 13083-878
lnstituto Estadual de Hematologia Arthur de Siqueira Cavalcanti - HEMORIO Recruiting
Rio de Janeiro, Brazil, 20211-030
Canada, Ontario
McMaster University Medical Centre - Hamilton Health Sciences Recruiting
Hamilton, Ontario, Canada, L8N 3Z5
St. Michael's Hospital Recruiting
Toronto, Ontario, Canada, M5B 1W8
France
CHRU de Brest - Hôpital Morvan Recruiting
Brest, France, 29200
Hôpital Cardiologique Louis Pradel Recruiting
Bron, France, 69677
Hôpital Timone - Enfants Not yet recruiting
Marseille, France, 13005
CHU Hôtel-Dieu Recruiting
Nantes Cedex 1, France, 44093
Hopital Necker, Hematologie Adultes Recruiting
Paris, France, 75015
Germany
Vivantes Klinikum Friedrichshain Recruiting
Berlin, Germany, 10249
Universitatsklinikum Bonn. Anstalt des oeffentlichen Rechts Recruiting
Bonn, Germany, 53127
Universitaetsklinikum Frankfurt, Goethe-Universitaet Not yet recruiting
Frankfurt/Main, Germany, 60590
Greece
General Hospital of Athens "Hippokration" Recruiting
Athens, Attica, Greece, 11527
General Hospital of Athens "LAIKO", 2nd Regional Blood Transfusion Center Recruiting
Athens, Attica, Greece, 11527
Israel
The Chaim Sheba Medical Center, The National Hemophilia Center Recruiting
Tel-Hashomer, Israel, 5262000
Italy
SODc. Malattie Emorragiche e della Coagulazione Centro di Riferimento Regionale per le Recruiting
Firenze, Italy, 50134
Azienda Ospedaliera Universitaria Federico II Recruiting
Napoli, Italy, 80131
Università degli studi di Roma "La Sapienza"- Policlinico Umberto I Recruiting
Roma, Italy, 00161
Japan
Nagoya University Hospital - Transfusion Medicine Recruiting
Nagoya, Aichi, Japan, 466-8560
Sapporo Tokushukai Hospital Not yet recruiting
Sapporo, Hokkaido, Japan, 004-0041
Nara Medical University Hospital Active, not recruiting
Kashihara, Nara, Japan, 634-8522
Saitama Medical University Hospital Recruiting
Iruma-gun, Saitama, Japan, 350-0495
National Center for Child Health and Development Recruiting
Setagaya-ku, Tokyo, Japan, 157-8535
Ogikubo Hospital Active, not recruiting
Suginami-ku, Tokyo, Japan, 167-0035
Korea, Republic of
Severance Hospital, Yonsei University Health System Recruiting
Seoul, Korea, Republic of, 03722
Kyung Hee University Hospital at Gangdong Active, not recruiting
Seoul, Korea, Republic of, 05278
Saudi Arabia
King Faisal Specialist Hospital & Research Center Recruiting
Riyadh, Saudi Arabia
Spain
Hospital Universitari Vall d´Hebrón Recruiting
Barcelona, Spain, 08035
H.U. La Paz. Recruiting
Madrid, Spain, 28046
H.U. Rio Hortega Recruiting
Valladolid, Spain, 47012
Sweden
Skåne University Hospital Recruiting
Malmö, Sweden, 205 02
Taiwan
Kaohsiung Medical University Chung-Ho Memorial Hospital Recruiting
Kaohsiung, Taiwan, 807
Taichung Veterans General Hospital Active, not recruiting
Taichung, Taiwan, 40705
National Taiwan University Hospital Recruiting
Taipei, Taiwan, 10002
Turkey
Ege Universitesi Tip Fakultesi Cocuk Sagligi Ve Hastaliklari Anabilim Dali Pediatric Hematoloji Active, not recruiting
Bornova, İ̇zmir, Turkey, 35040
Ege Universitesi Tip Fakultesi Hematoloji BD Active, not recruiting
Bornova, İ̇zmir, Turkey, 35040
Acibadem Adana Hospital, Department of Pediatric Hematology Active, not recruiting
Adana, Turkey, 01130
Akdeniz University Medical Faculty Hospital Terminated
Antalya, Turkey, 07070
Gaziantep University Sahinbey Training and Research Hospital Active, not recruiting
Gaziantep, Turkey, 27310
Istanbul University Oncology Institute Recruiting
Istanbul, Turkey, 34093
United Kingdom
Newcastle upon Tyne Hospitals NHS Foundation Trust Recruiting
Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE1 4LP
Non Malignant Haematology Research Unit Recruiting
Newcastle upon Tyne, Tyne & Wear, United Kingdom, NE1 4LP
Clinical Research Facility Recruiting
Glasgow, United Kingdom, G31 2ER
Department of Haematology Recruiting
Glasgow, United Kingdom, G4 0SF
Guy's and St Thomas' NHS Foundation Trust Recruiting
London, United Kingdom, SE1 7EH
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03587116    
Other Study ID Numbers: C0371004
2017-001271-23 ( EudraCT Number )
NAB PROTOCOL ( Other Identifier: Alias Study Number )
First Posted: July 16, 2018    Key Record Dates
Last Update Posted: August 31, 2021
Last Verified: August 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked